Uricon CR5mg
Type:Tablet
Generic Name:Oxybutynin Hydrochloride
Manufacturer:Beximco Pharmaceuticals Ltd.
Price:৳6.02
Indication
Overactive bladder
Administration
May be taken with or without food.
Adult Dose
Oral Overactive bladder Adult: As extended-release preparation: Initially, 5 mg once daily increased by 5 mg every wk if necessary to max 30 mg daily.
Child Dose
Oral Detrusor Overactivity, Nocturnal enuresis Bladder overactivity associated with a neurologic condition (eg, spina bifida) Child >6 years (extended-release): 5 mg/day PO initially; may be increased by 5 mg/day at weekly intervals; not to exceed 20 mg/day
Contraindication
GI obstruction or atrophy, severe toxic megacolon, significant bladder outflow obstruction, glaucoma, urinary retention.
Mode of Action
Oxybutynin exerts direct antispasmodic effect on the smooth muscle by inhibiting the muscarinic action of acetylcholine. It exhibits moderate anticholinergic effect, but has potent antispasmodic effects on urinary smooth muscle.
Precaution
Elderly; hepatic or renal impairment; neuropathy; hyperthyroidism; prostatic hyperplasia; hiatus hernia; cardiac disease, reflux oesophagitis, ulcerative colitis, myasthenia gravis; pregnancy and lactation. High environmental temperature might cause heat prostration (fever with heat stroke due to decreased sweating). Lactation: Unknown; use with caution
Side Effect
>10% Dry mouth (21-71%),Constipation (7-15%),Somnolence (2-14%),Nausea (2-12%) 1-10% Asthenia (6-10%),Dizziness (6-10%),Headache (6-10%),Blurred vision (6-10%),Dry eyes (6-10%),Diarrhea (6-10%),Nausea (6-10%),Pain (6-10%),Rhinitis (6-10%) <1% Anorexia,Fluid retention,Hot flush,Dysphonia,Dysphagia,Frequent bowel movements,Chest discomfort,Thirst Frequency Not Defined Cycloplegia,Impairment of mental alertness,Memory impairment,Mydriasis,Tachycardia,QT prolongation
Interaction
Co-administration with other anticholinergic drugs may cause undesirable increased anticholinergic effects. Additive sedation with CNS depressants and alcohol. Concentration may be increased by CYP3A4 inhibitirs (e.g. imidazole antifungals, macrolide antibiotics).